在尤土卜晃荡发现了这个channel→thegeekischic，喜欢。最新上传的Everything Wrong With Influencer Hauls 我要多看几遍
1. influencers do not pay for their hauls. yet haul is something to inspire you. luxury goods is something to treat you.
2. something good about social media is 'authenticity'.
3. influencers do not put things in the same way when you buy something on your own money. what you should consider, long-lasting, functional, comfortable, versatile..
4.the haul thing strips fashion from its value, which defines it through quantity not quality
5. influencers do not claim their hauls properly.
as a conculsion, DO NOT MAKE STUPID PURCHASE DECISION AND DO NOT THROW SHIT TON MONEY ON THINGS
1. influencers do not pay for their hauls. yet haul is something to inspire you. luxury goods is something to treat you.
2. something good about social media is 'authenticity'.
3. influencers do not put things in the same way when you buy something on your own money. what you should consider, long-lasting, functional, comfortable, versatile..
4.the haul thing strips fashion from its value, which defines it through quantity not quality
5. influencers do not claim their hauls properly.
as a conculsion, DO NOT MAKE STUPID PURCHASE DECISION AND DO NOT THROW SHIT TON MONEY ON THINGS
真的不喜欢老师有时候为了拉近关系，听起来更亲切一些，把15-18岁的高中生叫小朋友，尤其是有些学生高三的时候已经满18岁了。英语语境的正式场合下，他们的title都是Mr. XXX / Miss XXX.
这个年纪需要知道自己马上变成年人，要对自己负责，而不是一遍遍由外界加强“我还是小孩”这个概念。If you treat him like a child, he will act like a child.
这个年纪需要知道自己马上变成年人，要对自己负责，而不是一遍遍由外界加强“我还是小孩”这个概念。If you treat him like a child, he will act like a child.
#德国疫情##全球疫情# 临床前期研究证明瑞德西韦有效
［Pharmaceutical technology］在美国进行的一项临床前研究发现，吉利德科学公司的抗病毒候选药物瑞德西韦可以预防感染新冠病毒（Covid-19）的猕猴的疾病进展。
研究先用新冠病毒（SARS-CoV-2）感染动物。
美国国立卫生研究院（NIH）公布的数据显示，使用研究抗病毒药治疗猴子的临床表现较轻，肺部损伤减少。
临床前研究涉及在瑞德西韦的临床试验中用于治疗住院的Covid-19患者的剂量和治疗程序。美国国立卫生研究院国家过敏和传染病研究所（NIAID）正在主持该试验。
在临床前研究中，一组猴子接受了瑞德西韦，而另一组猴子则作为未治疗的比较，但均感染了新型冠状病毒。
感染后12小时，给治疗组一定剂量的瑞德西韦静脉注射，然后在接下来的6天中每天给予一次静脉加强剂量。
根据NIH，该研究是在病毒在肺部达到最高水平之前不久就进行了初步治疗。
A preclinical study in the US found that Gilead Sciences’ antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.
The animals were infected with the novel coronavirus, SARS-CoV-2.
Data announced by the National Institutes of Health (NIH) revealed a significant decrease in clinical disease and reduced lung damage in monkeys treated with the investigational antiviral drug.
The preclinical study involved dosing and treatment procedures being used in a clinical trial of remdesivir to treat hospitalised Covid-19 patients. NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is leading the trial.
In the preclinical study, one group of monkeys were given remdesivir while the second group acted as an untreated comparison arm, both infected with the novel coronavirus.
The treatment group was administered a dose of intravenous remdesivir 12 hours after infection, followed by a daily intravenous booster dose for the next six days.
According to the NIH, initial treatment was given shortly before the virus reached its highest level in the lungs.
［Pharmaceutical technology］在美国进行的一项临床前研究发现，吉利德科学公司的抗病毒候选药物瑞德西韦可以预防感染新冠病毒（Covid-19）的猕猴的疾病进展。
研究先用新冠病毒（SARS-CoV-2）感染动物。
美国国立卫生研究院（NIH）公布的数据显示，使用研究抗病毒药治疗猴子的临床表现较轻，肺部损伤减少。
临床前研究涉及在瑞德西韦的临床试验中用于治疗住院的Covid-19患者的剂量和治疗程序。美国国立卫生研究院国家过敏和传染病研究所（NIAID）正在主持该试验。
在临床前研究中，一组猴子接受了瑞德西韦，而另一组猴子则作为未治疗的比较，但均感染了新型冠状病毒。
感染后12小时，给治疗组一定剂量的瑞德西韦静脉注射，然后在接下来的6天中每天给予一次静脉加强剂量。
根据NIH，该研究是在病毒在肺部达到最高水平之前不久就进行了初步治疗。
A preclinical study in the US found that Gilead Sciences’ antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.
The animals were infected with the novel coronavirus, SARS-CoV-2.
Data announced by the National Institutes of Health (NIH) revealed a significant decrease in clinical disease and reduced lung damage in monkeys treated with the investigational antiviral drug.
The preclinical study involved dosing and treatment procedures being used in a clinical trial of remdesivir to treat hospitalised Covid-19 patients. NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is leading the trial.
In the preclinical study, one group of monkeys were given remdesivir while the second group acted as an untreated comparison arm, both infected with the novel coronavirus.
The treatment group was administered a dose of intravenous remdesivir 12 hours after infection, followed by a daily intravenous booster dose for the next six days.
According to the NIH, initial treatment was given shortly before the virus reached its highest level in the lungs.
✋热门推荐